Market Cap | 3.74B | P/E | - | EPS this Y | 1.10% | Ern Qtrly Grth | - |
Income | -133.09M | Forward P/E | -69.32 | EPS next Y | 59.90% | 50D Avg Chg | 1.00% |
Sales | 37.28M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 63.00% |
Dividend | N/A | Price/Book | 15.68 | EPS next 5Y | - | 52W High Chg | - |
Recommedations | 3.00 | Quick Ratio | 4.38 | Shares Outstanding | 71.92M | 52W Low Chg | 248.00% |
Insider Own | 12.01% | ROA | -18.55% | Shares Float | 58.98M | Beta | 1.23 |
Inst Own | 84.39% | ROE | -46.96% | Shares Shorted/Prior | 7.61M/6.92M | Price | 51.99 |
Gross Margin | -92.76% | Profit Margin | - | Avg. Volume | 2,578,060 | Target Price | 52.00 |
Oper. Margin | -353.17% | Earnings Date | Feb 27 | Volume | 1,995,469 | Change | 0.00% |
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
Stifel | Hold | Aug 10, 22 |
SVB Leerink | Market Perform | Aug 5, 22 |
HC Wainwright & Co. | Neutral | Aug 5, 22 |
Canaccord Genuity | Hold | Aug 5, 22 |
Raymond James | Market Perform | Aug 5, 22 |
Raymond James | Strong Buy | May 6, 22 |
Raymond James | Strong Buy | Nov 10, 21 |
JP Morgan | Neutral | Oct 11, 21 |
SVB Leerink | Outperform | Oct 11, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Schall Thomas J. | President and CEO President and CEO | Aug 04 | Option | 14.28 | 130,000 | 1,856,400 | 2,523,352 | 08/08/22 |
Schall Thomas J. | President and CEO President and CEO | Aug 04 | Sell | 50.24 | 130,000 | 6,531,200 | 2,393,352 | 08/08/22 |
KANAYA SUSAN M | EVP, CFO and Sec. EVP, CFO and Sec. | Aug 04 | Option | 6.43 | 46,298 | 297,696 | 137,615 | 08/08/22 |
KANAYA SUSAN M | EVP, CFO and Sec. EVP, CFO and Sec. | Aug 04 | Sell | 50.17 | 46,298 | 2,322,771 | 91,317 | 08/08/22 |
Tyree James L | Director Director | Aug 04 | Sell | 50.22 | 10,000 | 502,200 | 9,138 | 08/08/22 |
Cappel Markus J. | Chief Bus. Officer &.. Chief Bus. Officer & Treasurer | Aug 04 | Sell | 50.22 | 7,564 | 379,864 | 87,658 | 08/08/22 |
Tyree James L | Director Director | Jun 09 | Sell | 25.94 | 3,863 | 100,206 | 19,138 | 06/13/22 |
Tyree James L | Director Director | May 20 | Option | 0.00 | 7,726 | 23,001 | 05/24/22 | |
Parker Geoffrey M. | Director Director | May 20 | Option | 0.00 | 7,726 | 21,076 | 05/24/22 | |
MCKINNELL HENRY A | Director Director | May 20 | Option | 0.00 | 7,726 | 72,749 | 05/24/22 | |
Jain Rita | EVP, Chief Medical O.. EVP, Chief Medical Officer | May 20 | Option | 0.00 | 7,726 | 35,863 | 05/24/22 | |
Parker Geoffrey M. | Director Director | May 02 | Option | 14.42 | 12,500 | 180,250 | 124,413 | 05/03/22 |
Jain Rita | EVP, Chief Medical O.. EVP, Chief Medical Officer | Mar 27 | Option | 0.00 | 5,251 | 28,137 | 03/29/22 | |
FECZKO JOSEPH M | Director Director | Jan 21 | Option | 15.16 | 37,500 | 568,500 | 148,127 | 01/25/22 |
Tyree James L | Director Director | Dec 17 | Option | 13.52 | 37,500 | 507,000 | 52,775 | 12/21/21 |
Tyree James L | Director Director | Dec 17 | Sell | 34.59 | 37,500 | 1,297,125 | 15,275 | 12/21/21 |
Schall Thomas J. | President and CEO President and CEO | Dec 01 | Option | 12.29 | 45,936 | 564,553 | 2,354,816 | 12/03/21 |
Tyree James L | Director Director | May 24 | Option | 0 | 4,660 | 17,729 | 05/24/21 | |
Parker Geoffrey M. | Director Director | Mar 08 | Sell | 57.62 | 31,910 | 1,838,654 | 12,690 | 03/08/21 |
Cappel Markus J. | Chief Bus. Officer &.. Chief Bus. Officer & Treasurer | Mar 03 | Option | 9.5 | 33,092 | 314,374 | 118,918 | 03/03/21 |
Cappel Markus J. | Chief Bus. Officer &.. Chief Bus. Officer & Treasurer | Mar 03 | Sell | 68.43 | 33,092 | 2,264,486 | 85,826 | 03/03/21 |
Edwards Thomas A. | Director Director | Mar 03 | Sell | 70.06 | 1,100 | 77,066 | 119,857 | 03/03/21 |
Kwan Pui San | Principal Acctg Offi.. Principal Acctg Officer | Mar 01 | Option | 10.31 | 3,347 | 34,508 | 6,579 | 03/01/21 |
Kwan Pui San | Principal Acctg Offi.. Principal Acctg Officer | Mar 01 | Sell | 68.49 | 3,347 | 229,236 | 3,232 | 03/01/21 |
Cappel Markus J. | Chief Bus. Officer &.. Chief Bus. Officer & Treasurer | Feb 11 | Option | 11.02 | 700 | 7,714 | 86,526 | 02/11/21 |
Cappel Markus J. | Chief Bus. Officer &.. Chief Bus. Officer & Treasurer | Feb 11 | Sell | 69.66 | 700 | 48,762 | 85,826 | 02/11/21 |
Cappel Markus J. | Chief Bus. Officer &.. Chief Bus. Officer & Treasurer | Feb 08 | Option | 11.02 | 9,625 | 106,068 | 93,246 | 02/08/21 |
Cappel Markus J. | Chief Bus. Officer &.. Chief Bus. Officer & Treasurer | Feb 08 | Sell | 67.37 | 9,625 | 648,436 | 85,826 | 02/08/21 |
Kwan Pui San | Principal Acctg Offi.. Principal Acctg Officer | Feb 08 | Sell | 65 | 3,347 | 217,555 | 3,232 | 02/08/21 |
Kwan Pui San | Principal Acctg Offi.. Principal Acctg Officer | Feb 08 | Option | 10.31 | 3,347 | 34,508 | 6,579 | 02/08/21 |
Edwards Thomas A. | Director Director | Feb 04 | Sell | 61 | 20,000 | 1,220,000 | 121,357 | 02/04/21 |
Cappel Markus J. | Chief Bus. Officer &.. Chief Bus. Officer & Treasurer | Jan 27 | Option | 11.02 | 1,375 | 15,152 | 87,201 | 01/27/21 |
Cappel Markus J. | Chief Bus. Officer &.. Chief Bus. Officer & Treasurer | Jan 27 | Sell | 67.03 | 1,375 | 92,166 | 85,826 | 01/27/21 |
Edwards Thomas A. | Director Director | Dec 29 | Sell | 61.34 | 25,000 | 1,533,500 | 141,357 | 12/29/20 |
Schall Thomas J. | President and CEO President and CEO | Dec 16 | Option | 14.31 | 28,772 | 411,727 | 2,286,176 | 12/16/20 |
Schall Thomas J. | President and CEO President and CEO | Dec 16 | Sell | 65.02 | 28,772 | 1,870,755 | 2,268,557 | 12/16/20 |
Kwan Pui San | Principal Acctg Offi.. Principal Acctg Officer | Dec 16 | Option | 8.39 | 51,550 | 432,505 | 45,825 | 12/16/20 |
Kwan Pui San | Principal Acctg Offi.. Principal Acctg Officer | Dec 16 | Sell | 65.04 | 51,550 | 3,352,812 | 3,232 | 12/16/20 |